Connecticut 2024 Regular Session

Connecticut Senate Bill SB00241 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
3		-	LCO 1 of 2
	3	+	LCO No. 1536 1 of 2
4	4
5		-	General Assembly ~~Substitute~~ Bill No. 241
	5	+	General Assembly Raised Bill No. 241
6	6		February Session, 2024
	7	+	LCO No. 1536
7	8
	9	+
	10	+	Referred to Committee on PUBLIC HEALTH
	11	+
	12	+
	13	+	Introduced by:
	14	+	(PH)
8	15
9	16
10	17
11	18
12	19		AN ACT CONCERNING THE OFFICE OF HEALTH STRATEGY'S
13	20		RECOMMENDATIONS REGARDING 340B PROGRAM
14	21		TRANSPARENCY.
15	22		Be it enacted by the Senate and House of Representatives in General
16	23		Assembly convened:
17	24
18	25		Section 1. (NEW) (Effective October 1, 2024) (a) As used in this section, 1
19	26		(1) "federal 340B Drug Pricing Program" or "program" means the plan 2
20	27		described in Section 340B of the Public Health Service Act, 42 USC 256b, 3
21	28		as amended from time to time, and (2) "340B covered entity" means an 4
22	29		entity authorized to participate in the federal 340B Drug Pricing 5
23	30		Program under 42 USC 256b(a)(4), as amended from time to time. 6
24	31		(b) Not later than April 1, 2025, and annually thereafter, each 340B 7
25	32		covered entity shall report to the Health Systems Planning Unit of the 8
26	33		Office of Health Strategy, in a form and manner prescribed by the 9
27	34		executive director of the Office of Health Strategy, information 10
28	35		regarding such entity's participation in the federal 340B Drug Pricing 11
29		-	Program. Such report shall include (1) the aggregated acquisition cost 12
30		-	for prescription drugs obtained under the program, (2) the aggregated 13
31		-	payment amount received for prescription drugs obtained for and 14
32		-	dispensed to patients under the program, (3) the aggregated payments 15
33		-	made to pharmacies under contract to dispense prescription drugs 16
34		-	obtained under the program, (4) the number of claims for prescription 17
35		-	drugs described in subdivision (2) of this subsection, (5) if the 340B 18 Substitute Bill No. 241
	36	+	Program. Such report shall include the (1) aggregated acquisition cost 12
	37	+	for prescription drugs obtained under the program, (2) aggregated 13
	38	+	payment amount received for prescription drugs obtained for and 14 Raised Bill No. 241
36	39
37	40
38		-	LCO 2 of 2
39	41
	42	+	LCO No. 1536 2 of 2
	43	+
	44	+	dispensed to patients under the program, (3) aggregated payments 15
	45	+	made to pharmacies under contract to dispense prescription drugs 16
	46	+	obtained under the program, (4) number of claims for prescription 17
	47	+	drugs described in subdivision (2) of this subsection, and (5) if the 340B 18
40	48		covered entity is a hospital licensed pursuant to chapter 368v of the 19
41	49		general statutes, the national drug code number for the fifty most 20
42	50		frequently dispensed prescription drugs by the hospital under the 21
43		-	program, and (6) a description of programs and services offered by the 22
44		-	340B covered entity, including, but not limited to, programs and 23
45		-	services that support community access to care, that are funded in whole 24
46		-	or in part by savings gained through participation in the program and 25
47		-	that the 340B covered entity could not continue offering without such 26
48		-	savings. The information required to be reported pursuant to this 27
49		-	subsection shall (A) be disaggregated by payer mix, including, but not 28
50		-	limited to, Medicare, Medicaid and private insurance, as prescribed by 29
51		-	the executive director, and (B) include prescription drugs dispensed by 30
52		-	outpatient facilities that are child sites listed as reimbursable facilities 31
53		-	on a hospital's Medicare cost report. 32
54		-	(c) The executive director of the Office of Health Strategy shall post a 33
55		-	summary of the aggregate information received by the unit pursuant to 34
56		-	the provisions of this section on the Office of Health Strategy's Internet 35
57		-	web site. 36
	51	+	program. The information required to be reported pursuant to this 22
	52	+	subsection shall (A) be disaggregated by payer mix, including, but not 23
	53	+	limited to, Medicare, Medicaid and private insurance, as prescribed by 24
	54	+	the executive director, and (B) include prescription drugs dispensed by 25
	55	+	outpatient facilities that are child sites listed as reimbursable facilities 26
	56	+	on a hospital's Medicare cost report. 27
	57	+	(c) The executive director of the Office of Health Strategy shall post a 28
	58	+	summary of the aggregate information received by the unit pursuant to 29
	59	+	the provisions of this section on the Office of Health Strategy's Internet 30
	60	+	web site. 31
58	61		This act shall take effect as follows and shall amend the following
59	62		sections:
60	63
61	64		Section 1 October 1, 2024 New section
62	65
63		-	PH Joint Favorable Subst.
	66	+	Statement of Purpose:
	67	+	To require entities authorized to participate in the federal 340B Drug
	68	+	Pricing Program to report to the Health Systems Planning Unit of the
	69	+	Office of Health Strategy certain information regarding the program,
	70	+	including (1) aggregated acquisition costs, (2) aggregated payment
	71	+	information, (3) the number of claims for prescription drugs under the
	72	+	program, and (4) if the entity is a hospital, the national drug code
	73	+	number for the fifty most frequently dispensed prescription drugs by
	74	+	the hospital under the program.
	75	+	[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except
	76	+	that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not
	77	+	underlined.]
64	78